The European Medicines Agency (EMA) has designated allopurinol as the first orphan drug for the treatment of Marfan syndrome, a rare connective tissue disease which has no cure to date. This disease ...
One of the priority objectives of research into rare diseases is to develop new treatments, and orphan medicines — which target conditions affecting no more than 5 in 10,000 people in the EU — provide ...
Marfan syndrome is a genetic condition. It occurs because of a mutation (change) in one of your genes that develops before you’re born. It’s a type of connective tissue disorder, meaning it affects ...
The European Medicines Agency (EMA) has designated allopurinol as the first orphan drug for the treatment of Marfan syndrome, a rare connective tissue disease which as no cure to date. This disease ...
The European Medicines Agency (EMA) has designated allopurinol as the first orphan drug for the treatment of Marfan syndrome, a rare connective tissue disease which as no cure to date. This disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback